SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is trending due to escalating geopolitical tensions in the Middle East, specifically following reports of US-Israeli strikes on Iran, which is fueling intense community debate about potential oil supply disruptions, particularly through the Strait of Hormuz. Investors are sharply divided between anticipating a significant oil price spike and expecting a 'sell the news' reversal.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund is surging as escalating Middle East tensions, including strikes on oil infrastructure and disruptions to the Strait of Hormuz, fuel community expectations of significant oil price spikes and a massive upward move for the sector.

ProShares Trust - ProShares Ultra Gold 2x Shares

ProShares Ultra Gold

UGL is trending as escalating geopolitical uncertainties and concerns over ongoing fiat currency debasement spur significant safe-haven demand, with the community actively discussing gold's strong upward momentum and the broader precious metals rally.

Codatta

XNY (Codatta) is drawing significant attention for its strong performance and resilience, often showing green metrics even when the broader crypto market faces pullbacks. The community is actively discussing its potential for further breakouts and new highs, driven by its utility in powering AI and decentralized science data projects, alongside recent exchange listings.

The centrifuge token model powers centrifuge, providing the framework needed to run the platform without reliance on a single point of failure, including the centrifuge team or Company, and to accelerate its utility. To accomplish this, centrifuge leverages the cryptoeconomic primitives of a native token called the centrifuge token (cfg), a nominated-proof-of-stake consensus algorithm that employs centrifuge to stake value, rewards for centrifuge adoption, and an on-chain governance mechanism that empowers centrifuge holders to guide the development of centrifuge.

Centrifuge

Centrifuge is trending following the launch of the world's first licensed S&P 500 Index Fund Token, a development hailed by the community as a monumental step for institutional adoption and a significant advancement in tokenizing real-world assets.

Direxion Shares ETF Trust - Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

GUSH is trending amid heightened speculation surrounding escalating Middle East geopolitical tensions and their potential impact on global oil supply routes, with the community actively discussing a significant upward move for oil and gas exploration and production.

Wheaton Precious Metals Corp. is a precious metals streaming company with the quality portfolio of long-life, low-cost assets. Its business model offers investors commodity price leverage and exploration upside but with a much lower risk profile than a traditional mining company. It operates through the following business segments: Gold, Silver, Palladium, Cobalt, and Other. Wheaton was founded by Peter Derek Barnes on December 17, 2004 and is headquartered in Vancouver, Canada.

Wheaton Precious Metals Corp

Wheaton Precious Metals is gaining attention amid soaring gold prices reaching all-time highs and silver breaking multi-decade resistance, amplifying interest in its asset-light streaming model. The community is discussing recent strong earnings, a robust balance sheet, and a series of analyst target increases, though some express skepticism about its short-term price movements relative to the broader precious metals sector.

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc

Aardvark Therapeutics is facing intense scrutiny and negative sentiment after voluntarily pausing its Phase 3 HERO trial for ARD-101 due to reversible cardiac safety signals observed in high-dose studies. The community is expressing significant concern about the drug's future and the company's prospects in the competitive Prader-Willi Syndrome treatment landscape.

OR Royalties, Inc. engages in the acquisition, mining, and exploration of precious metals, streams, and other royalties. It holds interests in the Canadian Malartic mine. The company was founded on April 29, 2014 and is headquartered in Montreal, Canada.

OR Royalties Inc.

Osisko Gold Royalties Ltd

Osisko Gold Royalties is attracting significant community interest following its joint acquisition of a major gold stream on SolGold's Cascabel project and the emergence of activist investor Elliott Management as a large stakeholder. This news, combined with robust preliminary Q2 results showcasing record cash margins, reinforces bullish sentiment for the stable gold royalty player.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

The defense community is buzzing about Kratos Defense & Security Solutions, navigating a recent substantial stock offering against a wave of new contracts for its leading drone and hypersonic systems. Investors are keenly focused on the company's pivotal role in evolving global defense priorities and the anticipated surge in military spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler

CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal...

CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex

CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex PR Newswire...

CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments

CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments PR Newswire REHOVOT, Israel, Feb. 17, 2026...

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING PR Newswire REHOVOT, Israel, Feb. 5, 2026...

<ul class="summary-bullets"><li>The workforce reduction plan is expected to impact 25% of the company’s workforce.</li><li>The company’s adjusted net loss per share in Q3 came in at $0.25, but analysts, on average, expected earnings of $0.15 per share.</li><li>The company reported revenue of $77,000 for the three months ended September.</li></ul>Shares of CollPlant Biotechnologies (CLGN) slumped 14% on Wednesday morning after the company reported third-quarter earnings below Wall Street expectations.The firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/collplant-biotechnologies-reports-2025-third-quarter-financial-results-and-provides-corporate-update-302626666.html">reported</a> revenue of $77,000 for the three months ended September, above the $4,000 reported in the corresponding quarter of 2024, but below an analyst estimate of $5.03 million, according to data from Fiscal AI.Adjusted net loss per share came in at $0.25, lower than the $0.33 loss reported in the corresponding quarter of 2024. Still, analysts, on average, were expecting the company to report earnings of $0.15 per share.<h2 class="st-heading-2">Cost-Cutting Efforts And Layoffs</h2>The company said it has initiated a cost-cutting and workforce-reduction plan, which is expected to result in about a 25% cut in its workforce."In 2026, CollPlant will prioritize its collaboration with AbbVie and continue advancing its own dermal filler product candidate… In parallel, we plan to actively seek a strategic partner to collaborate with us on the continued development of our novel regenerative breast implant product candidate," Collplant CEO Yehiel Tal said.CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The company's products are based on its recombinant human collagen. The company entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, in 2021."We remain highly encouraged by the additional results emerging from the preclinical studies of our commercial-size regenerative breast implants, as well as from the ongoing evaluations of our photocurable dermal filler program,” Tal added. The photocurable derma filler program is now in the final stages of preclinical testing, and the company is now preparing for the initial clinical studies, IT said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around <a href="https://stocktwits.com/symbol/CLGN">CLGN stock</a> stayed within the ‘bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘normal’ levels.CLGN stock is down 44% this year and by about 53% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nyxoah-sa-stock-rises-pre-market-after-cms-raises-reimbursement-for-sleep-disorder-therapy/cL538b3REWB">Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a smartphone displays the logo of CollPlant Biotechnologies Ltd., an Israel-based regenerative and aesthetic medicine company, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

CLGN Stock Crashed 14% Today – Disappointing Earnings, Workforce Reduction Plan Draws Investor Attention

The firm reported revenue of $77,000 for the three months ended September, above the $4,000 reported in the corresponding quarter of 2024, but below an analyst estimate of $5.03 million, according to data from Fiscal AI. 

Equity

The firm reported revenue of $77,000 for the three months ended September, above the $4,000 reported in the corresponding quarter of 2024, but below an analyst estimate of $5.03 million, according to data from Fiscal AI. 


COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE...

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS PR Newswire REHOVOT, Israel, Nov...

CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada

CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada PR Newswire...

First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk

First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk First-in-Kind Fully Humanized 3D Bioprinted Human Skin...

CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. It engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. Its products include VergenixSTR, VergenixFG, and Collink.3D. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.

CollPlant Biotechnologies Ltd - Ordinary Shares New

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

CLGN
CollPlant Biotechnologies Ltd - Ordinary Shares New

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CLGN News

CLGNCollPlant Biotechnologies Ltd - Ordinary Shares New